Consensus Zai Lab Limited Hong Kong S.E.

Stocks

9688

KYG9887T1168

Pharmaceuticals

Market Closed - Hong Kong S.E. 03:08:17 2026-11-13 am EST			5-day change	1st Jan Change
20.24 ^HKD	-3.71%		+10.24%	+48.28%

Nov. 13	Zai Lab Limited - Special Call
Nov. 13	Zai Lab Says Experimental Drug Reduced Activity of Protein Linked to Atopic Dermatitis by at Least 90%	MT

c3d46285.B1c_NAnRw3XJnuhhqFwSnTF8xJAOGUy19NZ8ZtIQ8kQ.RDZSBUq-mg2I76USmjFEqUIfkuE2ezyDnJQtCKN7kCpwMFlxS-SvEICtiw~8c1f4f5406ed596a1597beb0dfc15cea

Analysts' recommendations: Zai Lab Limited

Nov. 06	Zai Lab Q3 Performance Meets Expectations With Pivotal 2027 Ahead, UBS Says	MT
Jan. 07	UBS Initiates Zai Lab at Buy With $35 Price Target	MT
Nov. 04	Zai Lab updates on Amgen's bemarituzumab Phase 1B/3 Fortitude-102 study	RE
Nov. 04	Zai Lab Limited Announces Update on Amgen's Bemarituzumab Phase 1B/3 Fortuda-102 Study	CI
25-03-13	JPMorgan Adjusts Price Target on Zai Lab to $51 From $44, Keeps Overweight Rating	MT
25-03-03	BofA Securities Downgrades Zai Lab to Neutral	MT
24-07-12	JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating	MT
23-12-14	Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target	MT
23-10-26	Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating	MT
23-10-26	Goldman Sachs Lowers Price Target on Zai Lab to $73.34 From $82.47, Maintains Buy Rating	MT
23-08-10	Cantor Fitzgerald Initiates Coverage on Zai Lab With Overweight Rating, $70 Price Target	MT
23-06-12	BofA Adjusts Price Target on Zai Lab to $62.50 From $75, Maintains Buy Rating	MT
23-05-11	Citigroup Adjusts Price Target on Zai Lab to $130 From $138, Keeps Buy Rating	MT
23-03-16	JPMorgan Adjusts Price Target on Zai Lab to $70 From $79, Maintains Overweight Rating	MT
22-11-18	JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating	MT
22-11-11	Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating	MT
22-08-09	Citigroup Adjusts Zai Lab's Price Target to $199 From $193, Reiterates Buy Rating	MT
22-05-25	CSPC Pharma Shares Fall After Weaker 1Q Profit	DJ
22-05-12	Citigroup Adjusts Zai Lab Price Target to $193 From $198, Maintains Buy Rating	MT
22-05-11	SVB Securities Adjusts Zai Lab Price Target to $95 From $101, Maintains Outperform Rating	MT
22-05-06	Guggenheim Adjusts Price Target for Zai Lab to $85 From $134, Maintains Buy Rating	MT
22-04-21	SVB Leerink Adjusts Zai Lab Price Target to $101 From $102, Maintains Outperform Rating	MT
22-04-04	JPMorgan Lowers Zai Lab's Price Target to $112 From $136, Maintains Overweight Rating	MT
22-03-03	Analyst recommendations: Acushnet, Bristol-Myers Squibb, Intel, iQIYI, Polymetal...
22-03-02	SVB Leerink Adjusts Zai Lab Price Target to $102 From $194, Maintains Outperform Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+1.38%
	JOHNSON & JOHNSON					-2.22%
	ABBVIE INC.					+5.69%
	ROCHE HOLDING AG					-2.05%
	MERCK & CO., INC.					+9.32%
	NOVARTIS AG					-3.71%
	ASTRAZENECA PLC					+16.57%
	AMGEN INC.					-7.27%
	GILEAD SCIENCES, INC.					+3.98%
	Average					+2.41%
	Weighted average by Cap.					+1.97%